Insys Therapeutics Inc (INSY) : Healthinvest Partners Ab added new position in Insys Therapeutics Inc during the most recent quarter end. The investment management firm now holds 788,175 shares of Insys Therapeutics Inc which is valued at $12,484,692 , the company said in a statement filed on Jul 26, 2016 with the SEC.Insys Therapeutics Inc makes up approximately 5.48% of Healthinvest Partners Ab’s portfolio.
Other Hedge Funds, Including , American Century Companies Inc boosted its stake in INSY in the latest quarter, The investment management firm added 5,154 additional shares and now holds a total of 281,966 shares of Insys Therapeutics Inc which is valued at $4,466,341. Parametrica Management Ltd sold out all of its stake in INSY during the most recent quarter. The investment firm sold 33,562 shares of INSY which is valued $535,314. Juncture Wealth Strategies sold out all of its stake in INSY during the most recent quarter. The investment firm sold 12,847 shares of INSY which is valued $190,906.
Insys Therapeutics Inc opened for trading at $15.63 and hit $15.85 on the upside on Friday, eventually ending the session at $15.65, with a gain of 0.06% or 0.01 points. The heightened volatility saw the trading volume jump to 2,95,213 shares. Company has a market cap of $1,120 M.
On the company’s financial health, Insys Therapeutics Inc reported $0.11 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Apr 28, 2016. Analyst had a consensus of $0.10. The company had revenue of $62.00 million for the quarter, compared to analysts expectations of $61.31 million. The company’s revenue was down -12.4 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $0.63 EPS.
Insys Therapeutics Inc. is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company has two marketed products: Subsys a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and Dronabinol SG Capsule a generic equivalent to Marinol (dronabinol) an approved second-line treatment of chemotherapy-induced nausea and vomiting (CINV) and anorexia associated with weight loss in patients with AIDS. The Companys lead product candidate is Dronabinol oral solution an orally administered liquid formulation of dronabinol. Dronabinol oral solution has demonstrated more rapidly detectable blood levels and a more reliable absorption profile than Marinol in its clinical studies.